BACKGROUND: The endothelial nitric oxide synthase cofactor tetrahydrobiopterin (BH4) is essential for maintenance of enzymatic function. We hypothesized that induction of BH4 synthesis might be an endothelial defense mechanism against inflammation in vascular disease states. METHODS AND RESULTS: In Study 1, 20 healthy individuals were randomized to receive Salmonella typhi vaccine (a model of acute inflammation) or placebo in a double-blind study. Vaccination increased circulating BH4 and interleukin 6 and induced endothelial dysfunction (as evaluated by brachial artery flow-mediated dilation) after 8 hours. In Study 2, a functional haplotype (X haplotype) in the GCH1 gene, encoding GTP-cyclohydrolase I, the rate-limiting enzyme in biopterin biosynthesis, was associated with endothelial dysfunction in the presence of high-sensitivity C-reactive protein in 440 coronary artery disease patients. In Study 3, 10 patients with coronary artery disease homozygotes for the GCH1 X haplotype (XX) and 40 without the haplotype (OO) underwent S Typhi vaccination. XX patients were unable to increase plasma BH4 and had a greater reduction of flow-mediated dilation than OO patients. In Study 4, vessel segments from 19 patients undergoing coronary bypass surgery were incubated with or without cytokines (interleukin-6/tumor necrosis factor-α/lipopolysaccharide) for 24 hours. Cytokine stimulation upregulated GCH1 expression, increased vascular BH4, and improved vasorelaxation in response to acetylcholine, which was inhibited by the GTP-cyclohydrolase inhibitor 2,4-diamino-6-hydroxypyrimidine. CONCLUSIONS: The ability to increase vascular GCH1 expression and BH4 synthesis in response to inflammation preserves endothelial function in inflammatory states. These novel findings identify BH4 as a vascular defense mechanism against inflammation-induced endothelial dysfunction.
BACKGROUND: The endothelial nitric oxide synthase cofactor tetrahydrobiopterin (BH4) is essential for maintenance of enzymatic function. We hypothesized that induction of BH4 synthesis might be an endothelial defense mechanism against inflammation in vascular disease states. METHODS AND RESULTS: In Study 1, 20 healthy individuals were randomized to receive Salmonella typhi vaccine (a model of acute inflammation) or placebo in a double-blind study. Vaccination increased circulating BH4 and interleukin 6 and induced endothelial dysfunction (as evaluated by brachial artery flow-mediated dilation) after 8 hours. In Study 2, a functional haplotype (X haplotype) in the GCH1 gene, encoding GTP-cyclohydrolase I, the rate-limiting enzyme in biopterin biosynthesis, was associated with endothelial dysfunction in the presence of high-sensitivity C-reactive protein in 440 coronary artery disease patients. In Study 3, 10 patients with coronary artery disease homozygotes for the GCH1 X haplotype (XX) and 40 without the haplotype (OO) underwent S Typhi vaccination. XX patients were unable to increase plasma BH4 and had a greater reduction of flow-mediated dilation than OO patients. In Study 4, vessel segments from 19 patients undergoing coronary bypass surgery were incubated with or without cytokines (interleukin-6/tumor necrosis factor-α/lipopolysaccharide) for 24 hours. Cytokine stimulation upregulated GCH1 expression, increased vascular BH4, and improved vasorelaxation in response to acetylcholine, which was inhibited by the GTP-cyclohydrolase inhibitor 2,4-diamino-6-hydroxypyrimidine. CONCLUSIONS: The ability to increase vascular GCH1 expression and BH4 synthesis in response to inflammation preserves endothelial function in inflammatory states. These novel findings identify BH4 as a vascular defense mechanism against inflammation-induced endothelial dysfunction.
Authors: Joseph Yeboah; Aaron R Folsom; Gregory L Burke; Craig Johnson; Joseph F Polak; Wendy Post; Joao A Lima; John R Crouse; David M Herrington Journal: Circulation Date: 2009-07-27 Impact factor: 29.690
Authors: W Maier; F Cosentino; R B Lütolf; M Fleisch; C Seiler; O M Hess; B Meier; T F Lüscher Journal: J Cardiovasc Pharmacol Date: 2000-02 Impact factor: 3.105
Authors: Sean O Hynes; Leslie A Smith; Darcy M Richardson; Imre Kovesdi; Timothy O'Brien; Zvonimir S Katusic Journal: Am J Physiol Heart Circ Physiol Date: 2003-10-09 Impact factor: 4.733
Authors: F Cosentino; D Hürlimann; C Delli Gatti; R Chenevard; N Blau; N J Alp; K M Channon; M Eto; P Lerch; F Enseleit; F Ruschitzka; M Volpe; T F Lüscher; G Noll Journal: Heart Date: 2007-10-04 Impact factor: 5.994
Authors: James H Stein; Heather J Ribaudo; Howard N Hodis; Todd T Brown; Thuy Tien T Tran; Mingzhu Yan; Elizabeth Lauer Brodell; Theodore Kelesidis; Grace A McComsey; Michael P Dube; Robert L Murphy; Judith S Currier Journal: AIDS Date: 2015-09-10 Impact factor: 4.177
Authors: Sae Young Jae; Eun Sun Yoon; Soo Jin Jung; Sol Gi Jung; Soo Hyun Park; Byung Sung Kim; Kevin S Heffernan; Bo Fernhall Journal: Eur J Appl Physiol Date: 2013-04-25 Impact factor: 3.078
Authors: Jordan D Miller; Yi Chu; Lauren E Castaneda; Kristine M Serrano; Robert M Brooks; Donald D Heistad Journal: Arterioscler Thromb Vasc Biol Date: 2013-01-10 Impact factor: 8.311
Authors: Jennifer K Bendall; Gillian Douglas; Eileen McNeill; Keith M Channon; Mark J Crabtree Journal: Antioxid Redox Signal Date: 2014-03-14 Impact factor: 8.401
Authors: Nicholas W Morrell; Stephen L Archer; Albert Defelice; Steven Evans; Monica Fiszman; Thomas Martin; Muriel Saulnier; Marlene Rabinovitch; Ralph Schermuly; Duncan Stewart; Hubert Truebel; Gennyne Walker; Kurt R Stenmark Journal: Pulm Circ Date: 2013-01 Impact factor: 3.017